Obesity: New life for antidiabetic drugs

Nature. 2010 Jul 22;466(7305):443-4. doi: 10.1038/466443a.

Abstract

Anti-diabetic drugs that activate the protein PPARγ had a bright start but soon lost appeal due to undesirable side effects. Subtle modifications may once again make them suitable for treating diabetes.

Publication types

  • News
  • Comment

MeSH terms

  • Adipose Tissue / cytology
  • Adipose Tissue / drug effects
  • Adipose Tissue / metabolism
  • Animals
  • Cyclin-Dependent Kinase 5 / antagonists & inhibitors*
  • Cyclin-Dependent Kinase 5 / metabolism
  • Diabetes Mellitus, Experimental / complications
  • Diabetes Mellitus, Experimental / drug therapy*
  • Diabetes Mellitus, Experimental / metabolism
  • Dietary Fats / pharmacology
  • Humans
  • Insulin / metabolism
  • Ligands
  • Mice
  • Obesity / complications
  • Obesity / metabolism*
  • Obesity / physiopathology
  • PPAR gamma / agonists
  • PPAR gamma / metabolism*
  • Phosphorylation / drug effects
  • Rosiglitazone
  • Thiazolidinediones / adverse effects
  • Thiazolidinediones / pharmacology*
  • Thiazolidinediones / therapeutic use

Substances

  • Dietary Fats
  • Insulin
  • Ligands
  • PPAR gamma
  • Thiazolidinediones
  • Rosiglitazone
  • Cyclin-Dependent Kinase 5